Evaluation of hepatic changes and local and systemic immune responses in goats immunized with recombinant Peroxiredoxin (Prx) and challenged with Fasciola hepatica |
| |
Authors: | Ricardo E Mendes Rafael A Pérez-Écija Rafael Zafra Leandro Buffoni Álvaro Martínez-Moreno John P Dalton Grace Mulcahy José Pérez |
| |
Institution: | 1. Department of Anatomy and Comparative Pathology, School of Veterinary Medicine, University of Cordoba, Animal Health Building, Campus Rabanales, Cordoba, Spain;2. Parasitology Unit, Department of Animal Health, School of Veterinary Medicine, University of Cordoba, Animal Health Building, Campus Rabanales, Cordoba, Spain;3. Institute of Parasitology, McGill University, Sainte Anne de Bellevue, Canada;4. Veterinary Sciences Centre, School of Agriculture, Food Science and Veterinary Medicine, College of Life Sciences, University College Dublin, Dublin, Ireland |
| |
Abstract: | Protection against Fasciola hepatica in goats immunized with Peroxiredoxin (Prx) was assessed. The experimental trial consisted of three groups of seven animals; group 1 were unimmunized and uninfected, group 2 were immunized with adjuvant only and group 3 were immunized with recombinant Prx in adjuvant (immunized and infected). Immunization with Prx in Quil A adjuvant, group 3, induced a reduction in fluke burden of 33.04% when compared to adjuvant control, group 2, although this difference was not significant. The hepatic gross and microscopical morphometric study revealed lower damage in the Prx-immunized compared to group 2 (p < 0.05). Furthermore, immunohistochemical studies revealed that the Prx-immunized group exhibited reduced infiltration of CD4+, CD8+, IFN-γ+ and TCR+ (p < 0.05); and CD2+ and IL-4+ (p < 0.001) in hepatic lesions. Levels of anti-Prx serum IgG in group 3 showed a significant increase at the 4th week after challenge infection compared with group 2 (p < 0.0001). This is the first report of ruminant immunization with recombinant Prx of F. hepatica. The study shows that this vaccine significantly reduces hepatic damage and encourages further studies to improve the vaccine efficacy. |
| |
Keywords: | Prx Fasciola hepatica Vaccine |
本文献已被 ScienceDirect 等数据库收录! |
|